Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Award - Doctoral Foreign Study Award (DFSA)

Direct Payment

$105,000.00

The role of the Ubiquitin-Editing Protein, A20, in Myelodysplastic Syndromes

EF 2013-14

Résumé
Myelodysplastic Syndromes (MDS) are heterogenous, blood cancers, which originate from a defective blood stem cell. They are defined by ineffective blood cell production, and frequently progress to Acute Myeloid Leukemia (AML). Among MDS patients, those with high-risk disease have the worst clinical outcomes and most limited treatment options, with a median overall survival of only 0.4 years. Current treatment options are ineffective at altering natural disease history, and have little positive impact on patient survival. In moving forward, the interrogation of key pathogenic signaling pathways will be necessary to generate breakthrough therapies, and thus realize this dire, unmet medical need. Recent epidemiological and empirical evidence, from our laboratory, among others, has made a clear connection between the activation of innate immune signaling and AML/MDS pathogenesis. This proposal seeks to examine how activated innate immune signaling can contribute to MDS, by studying A20, an important molecular switch in this pathway. Our preliminary data suggest that A20 levels are low in MDS patients; we hope to recapitulate this observation in mice, and hypothesize that A20 loss in these animals will lead to features of MDS. We believe that subsequent data from these studies will catalyze, and inform, the discovery of effective targeted medicines for the treatment of MDS. Both the heterogeneity of MDS and the lack of relevant pre-clinical disease models remain as major obstacles in generating effective therapies for this malignancy. This proposal outlines a specific mechanism, which may contribute to MDS transformation, while aiming to establish a novel pre-clinical MDS model. Valuable insight will be gained on how innate immune signaling activation, through A20 repression, may contribute to hematopoietic defects found in MDS. The research proposed will advance our understanding of causative molecular MDS determinants, while elucidating the contribution of A20 in MDS.
Programme
Doctoral Award - Doctoral Foreign Study Award (DFSA)
Bénéficiaire
Emplacement
Ohio, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
307804
Name
Rhyasen Garrett W
Region
Ohio
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
The role of the Ubiquitin-Editing Protein, A20, in Myelodysplastic Syndromes
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Doctoral Foreign Study Award (DFSA)
Keyworddelim
A20; Acute Myeloid Leukemia; Cancer Biology; Experimental Hematology; Genetic Mouse Models; Hematopoetic Stem Cell; Innate Immune Signaling; Myelodysplastic Syndromes; Nf-¿B
Abstract
Myelodysplastic Syndromes (MDS) are heterogenous, blood cancers, which originate from a defective blood stem cell. They are defined by ineffective blood cell production, and frequently progress to Acute Myeloid Leukemia (AML). Among MDS patients, those with high-risk disease have the worst clinical outcomes and most limited treatment options, with a median overall survival of only 0.4 years. Current treatment options are ineffective at altering natural disease history, and have little positive impact on patient survival. In moving forward, the interrogation of key pathogenic signaling pathways will be necessary to generate breakthrough therapies, and thus realize this dire, unmet medical need. Recent epidemiological and empirical evidence, from our laboratory, among others, has made a clear connection between the activation of innate immune signaling and AML/MDS pathogenesis. This proposal seeks to examine how activated innate immune signaling can contribute to MDS, by studying A20, an important molecular switch in this pathway. Our preliminary data suggest that A20 levels are low in MDS patients; we hope to recapitulate this observation in mice, and hypothesize that A20 loss in these animals will lead to features of MDS. We believe that subsequent data from these studies will catalyze, and inform, the discovery of effective targeted medicines for the treatment of MDS. Both the heterogeneity of MDS and the lack of relevant pre-clinical disease models remain as major obstacles in generating effective therapies for this malignancy. This proposal outlines a specific mechanism, which may contribute to MDS transformation, while aiming to establish a novel pre-clinical MDS model. Valuable insight will be gained on how innate immune signaling activation, through A20 repression, may contribute to hematopoietic defects found in MDS. The research proposed will advance our understanding of causative molecular MDS determinants, while elucidating the contribution of A20 in MDS.
Competitiondate
201310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Rhyasen, Garrett W
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~